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 Patients with uncontrolled severe persistent allergic asthma balance 
asthma control with adverse effects from treatment. 
 Omalizumab offers an effective alternative to stepping up treatment but 
at a substantial cost.  
 Although omalizumab is unlikely to be cost-effective for the overall 
patient population, it may be good value for money for severe 
subgroups. 
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 Evaluate cost-effectiveness of omalizumab for severe persistent asthma 
for the overall patient population covered by the marketing authorisation 
and relevant subgroups under the UK NHS perspective. 
 Omalizumab 75mg or 150mg solution for injection + optimised therapy 
vs optimised therapy alone (step 4 or step 5) 
 Assessment for response to treatment at 16 weeks: 
 Æ Non-responders should discontinue omalizumab 
Population and subgroups The model 
The inputs 
 Population reflects marketing authorisation 
 Patients uncontrolled at step 4 
 Patients controlled at step 5 
 Two age groups: 6-11 and  12 
 Population subgroups defined by indicators of severity: 
 Hospitalisation for asthma in past year 
 Maintenance OCS use (step 5) 
  3 exacerbations in the past year 
 
Effectiveness  
Double-blind 
placebo controlled 
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children 6-11 
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Open-label RCT EXALT 
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Population Age ICER, /QALY 
Overall 
6-11 years 98,072¼ 
 12 years 91,276¼ 
Hospitalisation 
6-11 years 54,324¼ 
 12 years 51,646¼ 
Maintenance OCS  12 years 58,712¼ 
 3 Exacerbations 
6-11 years 91,106¼ 
 12 years 89,094¼ 
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Asthma-related death 
Overall population 6-11 years
Overall population 12 years and
older
Hospitalisation subgroup 6-11 years
Hospitalisation subgroup 12 years
and older
Maintenance OCS subgroup 12
years and older
At least 3 exacerbations subgroup 6-
11 years
At least 3 exacerbations 12 years
and older
Upper threshold
Lower threshold
Base-case mortality
 Omalizumab improves the health outcomes of patients but at a high cost 
to the UK NHS. 
 ICERs were lower in more severe subgroup but still above conventional 
cost-effectiveness thresholds. 
 Asthma-related mortality is one of the key cost-effectiveness drivers: 
 ĹDVWKPD-related mortality Æ Ļ,&(5 
 
ICERs > conventional thresholds of 
cost-effectiveness used in the UK NHS 
of  23,400¼ (£20,000) and 35,100¼ 
(£30,000)/QALY 
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